Order Entry
Puerto Rico
ContactUsLinkComponent
SensoLyte® Rh110 DPPIV Assay Kit (Fluorimetric), AnaSpec Inc.
SensoLyte® Rh110 DPPIV Assay Kit (Fluorimetric), AnaSpec Inc.
Catalog # 103010-600
Supplier:  Anaspec Inc
CAS Number:  
SensoLyte® Rh110 DPPIV Assay Kit (Fluorimetric), AnaSpec Inc.
Catalog # 103010-600
Supplier:  Anaspec Inc
Supplier Number:  AS-72196-
CAS Number:  

Some Products May Appear Restricted

To ensure a smooth and speedy checkout, please log in to your account. Some items may show as restricted simply because you're not logged in.

If you do not have an account, you can register using our registration webform (https://www.avantorsciences.com/us/en/login/register)

 

If you're still seeing restrictions after logging in, certain products—like chemicals or medical devices—require additional account verification steps to be able to place an order. Some items may additionally require a specific license or customer documentation;  additional documentation will be requested for these items prior to shipment. 

Specifications

  • Size:
    100 Assays
  • Cat. No.:
    103010-600
  • Storage temperature:
    – 78 °C
  • Includes:
    The assays can be performed in a convenient 96-well microplate format, kit includes essential components and detailed protocol and references
  • Supplier no.:
    AS-72196

Specifications

About this item

DPPIV is a widely distributed serine protease that cleaves two amino acids from small peptides containing alanine or proline in the second position of the N-terminus of the peptide

The SensoLyte® Rh110 DPPIV Assay Kit provides a convenient method for high throughput screening of DPPIV inhibitors and for continuous assay of DPPIV activity utilizing a fluorogenic peptide. Upon enzyme cleavage, the peptide releases the Rh110 fluorophore with bright green fluorescence that can be detected at Ex/Em=490/520 nm. The longer-wavelength spectra and higher extinction coefficient of the Rh110 provide greater sensitivity and less interference from reaction components.

DPPIV activity is especially critical for inactivation of GLP-1, a potent antihyperglycemic hormone, inducing glucose-dependent stimulation of insulin secretion. DPPIV inhibitors provide a potent treatment for type 2 diabetes prolonging the activity of GLP-1 and improving insulin secretion and blood glucose control regulation.